PubRank

L A Moyé

Author PubWeight™ 58.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992 18.74
2 A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med 1993 3.75
3 Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999 3.26
4 Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997 3.13
5 Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998 2.97
6 Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994 2.74
7 Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 1997 1.96
8 Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994 1.67
9 Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998 1.63
10 Barriers to acute stroke therapy and stroke prevention in Mexican Americans. Stroke 2001 1.60
11 Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997 1.56
12 Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998 1.52
13 Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991 1.50
14 Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob Agents Chemother 1978 1.31
15 Comparison of stroke hospitalization rates among Mexican-Americans and non-Hispanic whites. Neurology 2000 1.24
16 Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites: the BASIC Project. Neurology 2004 1.20
17 High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. Am J Cardiol 1995 1.00
18 Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999 0.96
19 Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995 0.89
20 The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001 0.87
21 Carvedilol in patients with chronic heart failure. N Engl J Med 1996 0.87
22 Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity. Am J Cardiol 1994 0.83
23 The cardiac arrhythmia suppression trial. Casting suppression in a different light. Circulation 1995 0.83
24 Carvedilol and the Food and Drug Administration approval process: an introduction. Control Clin Trials 1999 0.82
25 Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999 0.81
26 Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998 0.81
27 Underestimation of the valvulopathy effect of fenfluramine. J Am Coll Cardiol 2000 0.77
28 Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991 0.76
29 Appetite-suppressant drugs and valvular heart disease. N Engl J Med 1999 0.75
30 Systolic Hypertension of the Elderly Program (SHEP). Part 9: Behavioral characteristics. Hypertension 1991 0.75
31 A scoring system for ascertainment of incident stroke; the Risk Index Score (RISc). Methods Inf Med 2006 0.75
32 Does body fatness modify the effect of dietary cholesterol on serum cholesterol? Results from the Chicago Western Electric Study. Am J Epidemiol 1993 0.75
33 Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Control Clin Trials 1993 0.75
34 Technology evolution: the technology spectrum and its application to orthopedic technologies. Int J Technol Assess Health Care 1999 0.75
35 Design of a randomized, placebo-controlled multicenter trial on the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction. Transdermal Nitroglycerin Investigators Group. Am J Cardiol 1998 0.75